Previous Close | 248.79 |
1-Year Change | 52% |
6-Months Change | 64.87% |
3-Months Change | -10.29% |
Moving Avg (50d) | 273.83 |
Moving Avg (200d) | 211.5 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 31.2B |
Beta (3-Years) | 0.89 |
Revenue Growth (ttm) | 79.37% |
Net Profit Margin (ttm) | -29.58% |
Return On Assets (ttm) | -13.28% |
EPS (ttm) | -4.14 |
PE Ratio (ttm) | -60.09 |
Dividend Yield | % |
Asset Description: | Alnylam Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-14 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
256.877 | 264.432 | 269.469 | 277.024 | 289.616 | 302.208 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.